肺癌和癌前病变组织芯片中Skp2蛋白的表达及其生物学意义

目的应用组织芯片技术结合免疫组化方法研究Skp2在肺癌和癌前病变组织芯片中的表达情况及其在肺癌中与各临床病理参数之间的关系，以便为肺癌的发生、发展、治疗及判断预后提供理论依据。方法应用免疫组织化学SP法检测自制270点肺癌及癌前病变组织芯片中Skp2蛋白的表达。应用SPSS11．5进行数据处理。结果（1）Skp2蛋白在各组表达的阳性率分别为：正常组0，癌前病变组16．7％（2／12），原发性肺癌组67．4％（60／89），淋巴结转移性肺癌组83．3％（10／12）；原发性肺癌组和淋巴结转移性肺癌组Skp2蛋白的阳性率均高于正常组和癌前病变组（均为P〈0．05）；而正常组与癌前病变组、原发性肺癌组与淋巴结转移性肺癌组之间Skp2蛋白表达差别无统计学意义（P〉0．05）。（2）原发性肺癌中Skp2在有淋巴结转移组表达的阳性率高于无淋巴结转移组（P〈0．05）；不同临床分期Skp2表达的阳性率不同，Ⅲ＋Ⅳ期高于Ⅰ＋Ⅱ期（P〈0．05）；Skp2的表达强度与肺癌临床分期呈正相关（P〈0．05）；而不同组织学类型、大体类型、年龄、性别及分化程度间Skp2表达的差异无统计学意义（均为P〉0．05）。结论（1）Skp2蛋白在原发性肺癌组与淋巴结转移性肺癌组中的阳性率均显著高于正常组与癌前病变组，提示其促进了肺癌的发生、发展，可以成为预测肺癌发生、发展的一个新指标，并可能成为肺癌基因治疗的新靶点。（2）原发性肺癌组中Skp2在有淋巴结转移组表达的阳性率高于无淋巴结转移组，Ⅲ＋Ⅳ期高于Ⅰ＋Ⅱ期，提示Skp2与肺癌的进展和侵袭性有关，对肺癌的临床预后估计具有一定的参考价值。

The Expression and Biological Significance of Skp2 in Tissue Microarray Including Lung Cancer and Precancerous Lesion

Objective In order to study the expressions of Skp2 in tissue microarray including lung cancer and precancerous lesion and the relationships between its expressions and clinicopathological parameters in primary lung cancer. With these results, we hope to be helpful for genesis, progress, gene therapy and prognosis evaluation of lung cancer. Methods We used SP immunohistochemistry method to detect the expressions of Skp2 in tissue microarray including lung cancer and precancerous lesion. All data were processed by SPSS 11.5 analysis soft ware. Results （1） Skp2 proteins were respectively detected in 0（0/10）, 16.7% （2/12）, 67.4% （60/89） and 83.3% （10/12） of normal lung tissue, precancerous lesion, primary lung cancer and lymph node metastasis of lung cancer; the positive rate of Skp2 protein in primary lung cancer and lymph node metastasis of lung cancer were significantly higher than that of normal lung tissue and precancerous lesion （P 〈 0.05）, but the positive rate of Skp2 protein had no significant difference between normal lung tissue and precancerous lesion or between primary lung cancer and lymph node metastasis of lung cancer （P 〉 0. 05 ）. （2） In primary lung cancer, the positive rate of Skp2 protein was significantly higher in the group with lymph node metastasis than that without lymph node metastasis （ P 〈 0. 05 ） ; it was higher in the group of Ⅲ ＋ Ⅳ stage than that in Ⅰ ＋ Ⅱ stage （P 〈 0. 05） ; the expression degrees of Skp2 protein had significantly positive correlation with the clinical stages of lung cancer （P 〈 0. 05 ）. But there were not significant difference between the groups of different histological types, gross types, ages, sexes and differentiation degrees （P 〉 0. 05）. Conclusion （ 1 ） The positive rate of Skp2 protein in primary lung cancer and lymph node metastasis of lung cancer are significantly higher than that of normal lung tissue and precancerous lesion, which suggests that Skp2 promote the genesis and progress of lung cancer; Skp2 may become a new target for gene therapy. （2） In primary lung cancer, the positive rate of Skp2 protein is significantly higher in the group with lymph node metastasis than that without lymph node metastasis, and it was higher in the group of Ⅲ ＋ Ⅳ stage than in Ⅰ ＋ Ⅱ stage. These suggests that Skp2 can promote the progress of lung cancer; Skp2 is related to the prognosis of lung cancer, which can be a reference in prognosis evaluation.